Browsing Tag
Tecentriq
7 posts
Genentech secures first ctDNA MRD-guided therapy approval for Tecentriq in MIBC
A cancer drug win is only half the story. Roche and Natera are testing whether ctDNA can decide who truly needs treatment.
May 15, 2026
NHS adopts 60-second Keytruda jab as Merck races to convert 14,000 UK patients before biosimilars hit
Merck's Keytruda patent expires in 2028. The NHS just gave it a 60-second injection to lock in patients before biosimilars arrive. The race is on.
May 9, 2026
Checkpoint inhibitors in early-stage cancer: A new era of adjuvant therapy is taking shape
Checkpoint inhibitors are redefining early-stage cancer care. Find out how Tecentriq, Keytruda, and others are competing for the adjuvant immunotherapy market.
June 4, 2025
Atezolizumab slashes colon cancer recurrence by 50% in ATOMIC trial: ASCO 2025 breakthrough
Genentech’s Tecentriq cuts recurrence risk by 50% in dMMR colon cancer, setting the stage for new adjuvant approvals after ATOMIC trial success.
June 3, 2025
Roche reports setback in lung cancer study with tiragolumab and tecentriq combination
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced disappointing results from the phase II/III SKYSCRAPER-06 study, aimed at…
July 7, 2024
NiKang Therapeutics, Roche partner for advanced liver cancer treatment trial
NiKang Therapeutics Inc., a clinical-stage biotech company specializing in small molecule oncology medicines, has announced a significant clinical…
December 9, 2023
Roche’s Tecentriq secures FDA approval for small cell lung cancer treatment
Roche’s subsidiary, Genentech, has announced a significant breakthrough with the US Food and Drug Administration (FDA) approval of…
March 30, 2019